
My lab develops statistical and computational approaches to understand how human genetic variation, in combination with the environment, leads to disease. Given their proxy for genetic liability itself, our primary focus is on the theory and application of Polygenic Risk Scores (PRS). In 2015, we published the popular PRS software, PRSice (‘precise’), followed in 2019 by PRSice-2 (PRSice website here). We have run several PRS workshops (eg. our PRS Summer School) and in 2020 we published our Guide to PRS paper, with accompanying PRS tutorial.
We believe that genetic liability to disease is more complex than implied by the additive model of present polygenic risk scores, that the interplay between the genome and the environment in causing disease needs to be better understood, and that analysis of diverse populations across diverse environments can provide the greatest power to understand the causes of disease.
The research in my lab follows 4 key themes:
For further information, please visit O’Reilly lab website
Education
BSc, Mathematics (First Class; Uni of Leeds, UK)
MSc, Genetic Epidemiology (Uni of Sheffield, UK. Supervisor: Chris Cannings)
PhD, Population Genetics (Imperial College London, UK. Supervisors: David Balding, Ewan Birney).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. O'Reilly did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.